Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.
Standard
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. / Mizukoshi, Eishiro; Eisenbach, Christoph; Edlin, Brian R; Newton, Kimberly P; Raghuraman, Sukanya; Weiler-Normann, Christina; Tobler, Leslie H; Busch, Michael P; Carrington, Mary; McKeating, Jane A; O'Brien, Thomas R; Rehermann, Barbara.
in: J INFECT DIS, Jahrgang 198, Nr. 2, 2, 2008, S. 203-212.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.
AU - Mizukoshi, Eishiro
AU - Eisenbach, Christoph
AU - Edlin, Brian R
AU - Newton, Kimberly P
AU - Raghuraman, Sukanya
AU - Weiler-Normann, Christina
AU - Tobler, Leslie H
AU - Busch, Michael P
AU - Carrington, Mary
AU - McKeating, Jane A
AU - O'Brien, Thomas R
AU - Rehermann, Barbara
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years). METHODS: HCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays. RESULTS: HCV-specific T cell proliferation and IFN-gamma production were more common in nonviremic EIA-positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003). They were also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P= .04) and 0 of 24 nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P= .0115) than those without nAbs, but these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses. CONCLUSION: The reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
AB - BACKGROUND: Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years). METHODS: HCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays. RESULTS: HCV-specific T cell proliferation and IFN-gamma production were more common in nonviremic EIA-positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003). They were also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P= .04) and 0 of 24 nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P= .0115) than those without nAbs, but these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses. CONCLUSION: The reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
M3 - SCORING: Zeitschriftenaufsatz
VL - 198
SP - 203
EP - 212
JO - J INFECT DIS
JF - J INFECT DIS
SN - 0022-1899
IS - 2
M1 - 2
ER -